Investing.comDoubao · 实盘可交易 · 做多市场:美股▼ 亏 -1.29% · 已结算把握 4/10
北京时间·🕒 发布 19:16:36·⟳ 抓取 19:17:18 +42s·⚡ 决策 10-15 19:22:52 +5m34s·12.3 天前
Krystal Biotech 公布 KB113 在 Gorlin 综合征三例试点中使逾八成基底细胞癌病灶缩小
官方通稿性质的三例早期阳性数据提供新适应症期权，盘前尚未明显定价；但样本极小、无对照且距收入很远，只适合试探仓并严格限制追高。
📄 原文Investing.com↗ 原文
Krystal Biotech reports positive early data for Gorlin syndrome trial
Can robust TSMC earnings help settle AI jitters? PITTSBURGH - Krystal Biotech, Inc. (NASDAQ:KRYS) reported today that o…
▼ 亏 -1.29%入场 10-15 盘前首笔 @333.20 → 离场 10-16 常规开盘 @329.28
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(价格在入场线上方)、绿底 = 亏
💡 交易逻辑KB113三例pilot阳性，盘前尚未定价，小仓博后续FDA开发期权
怎么买 限价买入 不高于昨收 +2%、2 个交易日内有效
怎么卖 止盈 +4%(半仓)/+8%(清仓) · 止损 -5% · 时间止损 5日
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做多 KRYS.US Krystal Biotech, Inc.
5 个交易日均已收盘,数据完整 · 美股含盘前盘后(灰底:美东 04:00 至收盘后 4 小时)
- 发布 10-15 19:16 北京(美东 10-15 07:16)
- 抓取 10-15 19:17 北京(美东 10-15 07:17)
- 决策 10-15 19:22 北京(美东 10-15 07:22)
- 入场 10-15 20:01 北京(美东 10-15 08:01) · 盘前首笔 @333.20
- 离场 10-16 21:30 北京(美东 10-16 09:30) · 常规开盘 @329.28
时间轴只含交易时段(午休、隔夜已压缩);横轴为北京时间,悬停看当地时间;蓝虚线 = 纸面入场价;建仓日图红线在昨收上方、绿线在下方
成交明细 · 纸面
做多 KRYS.US Krystal Biotech, Inc.
| 收益状态 | -1.29% 已平仓 |
|---|---|
| 进场成交 | 2026-10-15 · 盘前首笔 · 10-15 20:01 北京 · @333.204 |
| 离场成交 | 2026-10-16 · 常规开盘 · @329.281 |
| 毛收益 | -1.18% |
| 成本 | +0.12% |
| 净收益 | -1.29% |
| 计入收益 | -1.29% |
| 建仓日 | 2026-10-15 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-28 02:20
研究档案
结论摘要
KB113在Gorlin综合征三例患者中显示广泛病灶缩小和活检完全缓解，验证局部IL-2/IL-12免疫疗法的早期生物学信号；不过这仍是n=3、开放标签、研究者评估的试点，不能按注册成功定价，故仅以小probe参与。
消息传播链
- Stockwatch标注为公司News Release，发布时间为2026-10-15 07:00 ET；Barchart同步承载GlobeNewswire通稿文本。市场反应:07:08 ET盘前约327美元、较330.69美元前收低1.1%，仅8股成交，尚无有效市场反应。
- Investing在通稿后约16分钟发布AI辅助撰写、编辑审核的英文报道，属于转载扩散而非首发。
关键理由
- 新肿瘤项目从临床前/未验证状态推进到人体pilot阳性，且出现未注射病灶缩小和3个活检完全缓解，平台外溢想象空间强于普通安全性更新。
- 消息在美东盘前07:00发布，截至07:08盘前仅8股成交、价格约327美元，尚未形成有效重定价；同公司早期阳性临床先例曾在随后3–5日获得资金关注。
主要风险
- 仅3名患者、单臂开放标签且采用研究者评估，无法排除选择偏误、自然病程和测量主观性，后续对照试验可能证伪。
- KB113只处于与FDA讨论 advanced development 的阶段，没有IND/注册试验设计、峰值销售或近期收入指引，若开盘高开过多将显著损害赔率。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-15 · 影响 weakens
检索到基底细胞癌已有系统治疗和公司风险披露，但未找到能否认本次pilot数据的即时事实；主要反证仍是n=3、无对照和早期开发阶段。
检索:KB113 Krystal Biotech risks Gorlin syndrome basal cell carcinoma competitors Libtayo Odomzo Erivedge 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-10-15 · 影响 weakens
发布后初期主要是新闻稿/聚合转载，尚未检索到券商正式上调峰值销售或目标价，缺少基本面确认。
检索:Krystal Biotech KB113 analyst reaction October 15 2026 Gorlin syndrome pilot three patients 原文 ↗ - 做多前查反向 · 来源 kb_search · 影响 none
内部KB检索服务连接失败，未取得券商纪要或管线估值证据；该失败不改变公开事实，也不作为看多依据。
检索:Krystal Biotech KB113 Gorlin syndrome basal cell carcinoma pipeline market opportunity
先例如何影响了这次决策
对本次决策的影响:先例支持以probe而非AVOID捕捉早期临床期权，同时因样本极薄和当前数据更早，显著降低仓位与追高空间。
方向:唯一同公司、同市场、盘前早期阳性临床先例为正，+3/+5日超额收益明显，但样本仅1条且相似度只有6/10。
涨幅量级:不能用该先例的+10%以上涨幅直接设定目标价；本事件n=3且无对照，只采用更保守的4%–8%试探性止盈区间。
形态:该先例事件日仅小涨、随后资金逐步重估，未见首发当日高开低走；但单一样本无法确认稳定模式。
历史先例(按相似度)
- 相似度 6/10 KRYS 2026-01-08 Krystal Biotech盘前发布KB407 Phase 1 CORAL-1阳性中期更新，证明肺部野生型CFTR递送；事件前一日下跌1.21%，无明显抢跑。 原文 ↗
事件后 +1日 +1.0% · +2日 +6.1% · +3日 +10.5% · +4日 +18.5% · +5日 +18.4%
⚠未核对目标相位 — 该行涨幅别用来定止盈止损
相似度依据:同一公司、同一美股盘前时段且同为早期阳性临床更新，但KB407为Phase 1中期数据，当前KB113仅三例pilot，证据等级更弱。
经验:市场可能不会在事件日立即完全反映早期临床期权，同公司清晰阳性数据曾在随后数日继续重估。
工具执行结果 · 成功 17 · 降级 0 · 失败 1 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`krys kb113 basal cell carcinoma pedra | krystal biotech kb113 gorlin syndrome pilot data | krystal biotech kb113 il-2 il-12 intratumoral`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研 - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 636 ms
{ - web_search 成功 doubao_search · 1,876 ms
豆包搜索结果（原始查询:Krystal Biotech KB113 Gorlin syndrome pilot study press release October 15 2026；API SearchType:web） - web_search 成功 doubao_search · 2,048 ms
豆包搜索结果（原始查询:Krystal Biotech KB113 pipeline phase basal cell carcinoma Gorlin syndrome market cap 2026；API SearchType:web） - kb_search 失败 stock_tools HTTP · 69 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - web_search 成功 doubao_search · 1,733 ms
豆包搜索结果（原始查询:site:globenewswire.com Krystal Biotech positive clinical data pilot study shares 2024 2025 KB113；API SearchType:web） - web_search 成功 doubao_search · 2,523 ms
豆包搜索结果（原始查询:Krystal Biotech early phase data stock reaction next day positive pilot trial KRYS；API SearchType:web） - web_search 成功 doubao_search · 1,672 ms
豆包搜索结果（原始查询:Krystal Biotech Announces Positive Clinical Data KB113 GlobeNewswire October 15 2026；API SearchType:web） - web_search 成功 doubao_search · 1,077 ms
豆包搜索结果（原始查询:site:globenewswire.com "Krystal Biotech" "positive" "clinical data" "2026" dermatology gene therapy；API SearchType:web） - web_search 成功 doubao_search · 1,317 ms
web_search「site:ir.krystalbio.com/news-releases Krystal Biotech positive interim clinical update phase 1 2025 2026 stock」无结果。 - web_search 成功 doubao_search · 1,805 ms
豆包搜索结果（原始查询:KRYS shares rose clinical data pilot three patients gene therapy press release reaction；API SearchType:web） - web_search 成功 doubao_search · 1,895 ms
豆包搜索结果（原始查询:"Early Evidence of Monotherapy Activity" "Krystal" date NSCLC KB707；API SearchType:web） - web_search 成功 doubao_search · 1,426 ms
豆包搜索结果（原始查询:"Initial Clinical Update for Rare Respiratory Disease Programs" time ET December 12 2024 GlobeNewswire；API SearchType:web） - web_search 成功 doubao_search · 2,110 ms
豆包搜索结果（原始查询:Krystal Biotech positive pilot trial n=3 press release stock reaction biotech 2026；API SearchType:web） - event_study 成功 stock_tools HTTP · 16 ms
{ - web_search 成功 doubao_search · 2,285 ms
豆包搜索结果（原始查询:KB113 Krystal Biotech risks Gorlin syndrome basal cell carcinoma competitors Libtayo Odomzo Erivedge 2026；API SearchType:web） - web_search 成功 doubao_search · 1,881 ms
豆包搜索结果（原始查询:Krystal Biotech KB113 analyst reaction October 15 2026 Gorlin syndrome pilot three patients；API SearchType:web）
原文全文
展开原文 · 2,025 字
Can robust TSMC earnings help settle AI jitters?
PITTSBURGH - Krystal Biotech, Inc. (NASDAQ:KRYS) reported today that over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 in a pilot study, according to a press release statement.
The multicenter, single-arm, open label study enrolled three adult patients with Gorlin syndrome, a genetic disease characterized by increased risk of developing basal cell carcinomas. Patients received six doses of KB113 over 14 weeks.
At the final assessment conducted 30 days after the last dose, 69 of 83 assessed landmark lesions showed some degree of regression. Of these, 42 lesions demonstrated greater than 50% clinical regression, and eight lesions showed at least 90% clinical regression, as measured using an investigator-assessed 5-point clearance scale.
The company reported that substantial regression was observed in lesions that were not directly injected with KB113. One injected lesion from each patient that achieved at least 90% clinical regression was biopsied, and all three demonstrated complete response with no evidence of residual tumor tissue.
KB113 is an intratumoral immunotherapy designed to express interleukin-2 and interleukin-12 in the tumor microenvironment. The treatment was well tolerated, with all reported adverse events classified as mild or moderate in severity and transient in nature.
Gorlin syndrome patients can develop basal cell carcinomas as early as infancy and may have hundreds over their lifetimes. Available data suggest the number of patients with Gorlin syndrome in the United States could exceed 10,000.
The company has initiated discussions with the U.S. Food and Drug Administration regarding advanced clinical development of KB113 for Gorlin syndrome treatment. Study investigator Dr. Shireen Guide presented the data at the 14th PeDRA Annual Conference today.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
PITTSBURGH - Krystal Biotech, Inc. (NASDAQ:KRYS) reported today that over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 in a pilot study, according to a press release statement.
The multicenter, single-arm, open label study enrolled three adult patients with Gorlin syndrome, a genetic disease characterized by increased risk of developing basal cell carcinomas. Patients received six doses of KB113 over 14 weeks.
At the final assessment conducted 30 days after the last dose, 69 of 83 assessed landmark lesions showed some degree of regression. Of these, 42 lesions demonstrated greater than 50% clinical regression, and eight lesions showed at least 90% clinical regression, as measured using an investigator-assessed 5-point clearance scale.
The company reported that substantial regression was observed in lesions that were not directly injected with KB113. One injected lesion from each patient that achieved at least 90% clinical regression was biopsied, and all three demonstrated complete response with no evidence of residual tumor tissue.
KB113 is an intratumoral immunotherapy designed to express interleukin-2 and interleukin-12 in the tumor microenvironment. The treatment was well tolerated, with all reported adverse events classified as mild or moderate in severity and transient in nature.
Gorlin syndrome patients can develop basal cell carcinomas as early as infancy and may have hundreds over their lifetimes. Available data suggest the number of patients with Gorlin syndrome in the United States could exceed 10,000.
The company has initiated discussions with the U.S. Food and Drug Administration regarding advanced clinical development of KB113 for Gorlin syndrome treatment. Study investigator Dr. Shireen Guide presented the data at the 14th PeDRA Annual Conference today.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
62e7fe95b2· 2026-10-15 19:22 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前